Cargando…

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

Lung cancer is one of the deadliest malignant tumors with limited treatment options. Although targeted therapy, using tyrosine-kinase inhibitors such as erlotinib (Erlo), has shown therapeutic benefit, only 15 % patients with mutated epidermal growth factor receptor (EGFR) in lung cancer cells are s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaofei, Chen, Keqiang, Yu, Ying, Xiang, Yi, Kim, Jae Hong, Gong, Wanghua, Huang, Jiaqiang, Shi, Guochao, Li, Qingyun, Zhou, Min, Sayers, Thomas, Tewary, Poonam, Gao, Beili, Wang, Ji Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752504/ https://www.ncbi.nlm.nih.gov/pubmed/29312591 http://dx.doi.org/10.18632/oncotarget.22596

Ejemplares similares

Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
por: Mathew, Mohit P., et al.
Publicado: (2015)

The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract Cancer
por: Tian, Cuimeng, et al.
Publicado: (2020)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Requirement of CRAMP for mouse macrophages to eliminate phagocytosed E. coli through an autophagy pathway
por: Chen, Keqiang, et al.
Publicado: (2021)

Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
por: Suárez-Arroyo, Ivette J., et al.
Publicado: (2016)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Metformin and erlotinib synergize to inhibit basal breast cancer
por: Lau, Ying-Ka Ingar, et al.
Publicado: (2014)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
por: Xie, Shengzhi, et al.
Publicado: (2015)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen, Kim-Son H, et al.
Publicado: (2012)

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo
por: Jensen, Brian C., et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
por: Ikarashi, Nobutomo, et al.
Publicado: (2020)

Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma
por: Lin, Shuye, et al.
Publicado: (2021)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
por: Sorensen, Boe S, et al.
Publicado: (2014)

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
por: Daneshmanesh, Amir Hossein, et al.
Publicado: (2018)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma
por: Chen, Fangjun, et al.
Publicado: (2023)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
por: Padda, Sukhmani K., et al.
Publicado: (2021)

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
por: Bansal, Nitu, et al.
Publicado: (2015)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer
por: Tong, Dongdong, et al.
Publicado: (2023)

The G-Protein-Coupled Chemoattractant Receptor Fpr2 Exacerbates High Glucose-Mediated Proinflammatory Responses of Müller Glial Cells
por: Yu, Ying, et al.
Publicado: (2017)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
por: Slobbe, Paul, et al.
Publicado: (2015)

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model
por: Tan, Jianlong, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition
por: Wang, Edina, et al.
Publicado: (2019)

Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer
por: Xu, Yi-chao, et al.
Publicado: (2017)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2009)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner
por: Li, Kai, et al.
Publicado: (2022)

The Contribution of Chemoattractant GPCRs, Formylpeptide Receptors, to Inflammation and Cancer
por: Liang, Weiwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gav93gfbkot2p2cet3pugcmo0g